Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety
Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.
EP: 1.Clinical and Economic Burden of Schizophrenia
EP: 2.Symptoms Associated with Schizophrenia
EP: 3.Risk Factors for Schizophrenia
EP: 4.Challenges of Early and Accurate Diagnosis in Schizophrenia
EP: 5.Exploring Schizophrenia Progression and Its Impact on Quality of Life
EP: 6.Consequences of Relapse in Schizophrenia Care
EP: 7.Addressing Social Determinants of Health and Unmet Needs in Schizophrenia
EP: 8.Current Treatment Guidelines for Schizophrenia
EP: 9.First- and Second-Generation Antipsychotic Therapies and Treatment Sequencing
EP: 10.Switching Therapies, Managing Adverse Effects, and Adherence Challenges
Now Viewing
EP: 11.Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety
EP: 12.Use of Xanomeline/Trospium in Clinical Practice
EP: 13.Comparing Safety Profiles and Health Care Costs
EP: 14.Emerging Therapies in Schizophrenia
EP: 15.Addressing Access Barriers and Formulary Restrictions
EP: 16.Final Thoughts on Improving Access and Care
Panelists discuss how xanomeline/trospium chloride introduces a paradigm shift in schizophrenia therapy through selective muscarinic receptor activity, avoiding dopamine blockade.
Panelists discuss how phase 3 EMERGENT-2 and EMERGENT-3 trials demonstrated its efficacy in reducing psychotic symptoms with minimal metabolic or neurologic adverse effects.
Panelists discuss how this mechanism may redefine treatment options for patients who experience poor tolerability or limited response to existing dopamine-based therapies.
Related Videos
Related Content
